Indication

Dermatofibrosarcoma protuberans

Dermatofibrosarcoma protuberans is a rare, low- to intermediate-grade cutaneous soft tissue sarcoma originating in the dermis and subcutaneous tissues. Read more about Dermatofibrosarcoma protuberans

28 drugs 27 manufacturers

Advertisement

Drugs that treat it

Common Dermatofibrosarcoma protuberans therapies.

Showing 1–9 of 28 drugs

GLEEVEC (imatinib mesylate)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Novartis Pharmaceuticals

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
SUN PHARMA GLOB

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
APOTEX CORP

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
TEVA USA

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Mylan Pharmaceuticals

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
MYLAN INSTITUTI

IMATINIB MESYLATE

PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
NORTHSTAR RX LL

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Major Pharamceuticals

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
DR.REDDY'S LAB
Filter & compare in the drug finder →Opens the drug finder with Dermatofibrosarcoma protuberans preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Dermatofibrosarcoma protuberans.

Dermatofibrosarcoma protuberans is a rare, low- to intermediate-grade cutaneous soft tissue sarcoma originating in the dermis and subcutaneous tissues.

Most frequently developing on the trunk and proximal extremities of young to middle-aged adults, it typically manifests as an indurated, slow-growing cutaneous plaque that eventually progresses into multinodular, violaceous or flesh-colored protuberant masses.

Pathophysiologically, more than 90% of cases are driven by a chromosomal translocation, t(17;22)(q22;q13), or supernumerary ring chromosomes that fuse the *COL1A1* and *PDGFB* genes, generating continuous autocrine activation of the platelet-derived growth factor receptor-beta pathway.

Histologically characterized by CD34-positive spindle cells arranged in a distinctive storiform pattern, the neoplasm demonstrates infiltrative, tentacle-like local growth patterns that yield high rates of local recurrence despite a low propensity for distant metastasis.

Personalize your experience

Follow Dermatofibrosarcoma protuberans and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it